Evaluate Vantage Homepage
Medical device groups float – then sink
Medtechs rushed for the markets last year, but had an uneasy time once there.
UCB makes a rare acquisition
The Belgian group has bolstered its epilepsy offering with a $1.9bn move on Zogenix.
Cytokinetics hopes to resurrect omecamtiv
Almost in stealth mode, Cytokinetics has pressed on with the heart failure project, which now awaits a key regulatory catalyst.
Medtech
Medical device groups float – then sink
Medtechs rushed for the markets last year, but had an uneasy time once there.
Company Events
Proqr eyes its first big test
With pivotal sepofarsen data due, the group will hope to get one up on Editas.
Days of reckoning for immune checkpoint blockers
Can a trial carried out in China back a US approval? Investors in anti-PD-(L)1 players will find out soon enough.
Key data reveals for the small players
Praxis, Proqr and Nordic Nanovector are awaiting important data.
Interviews
Argenx’s independent streak approaches its biggest test
Armed with the first approval for an FcRn antagonist, the Belgian company’s chief executive remains convinced by a solo strategy.
Investors back Quell’s Treg approach
Quell should soon join Sangamo in the clinic, while a number of engineered Treg players are at the preclinical stage.
Global Blood takes on gene therapy
Proof-of-concept data at Ash should give clues about whether GBT021601 could be an oral functional cure for sickle cell disease.